NodThera was created and seed funded by life science investor, Epidarex Capital in 2016 based on earlier research conducted at Selvita, a Polish drug discovery company which remains a shareholder in NodThera.
NodThera is developing small molecule inhibitors of the NLRP3 inflammasome, a multi-protein complex which initiates an innate immune response in the body.
Its next generation approach could bring new treatment options to patients in areas where current standard of care is sub-optimal or non-existent across a wide range of therapeutic areas related to chronic inflammation.
The Chesterford Research Park-based company raised $40 million growth capital in a Series A round which was completed in June 2018. The Series A second closing was co-led by leading healthcare investors Sofinnova Partners and 5AM Ventures, with further participation from Epidarex Capital and F-Prime Capital Partners.
In addition to its Chesterford Research Park base, NodThera has offices in Seattle WA and Boston MA.
In May 2019, NodThera added Don Nicholson, former CEO of Nimbus Therapeutics as chair while Bicycle Therepeutics CEO Kevin Lee became an independent director.